Osteoarthritis and cardiometabolic diseases: shared mechanisms, modifiable risk factors, and integrated management strategies.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2026-04-01 Epub Date: 2026-03-24 DOI:10.1080/17512433.2026.2649611

Patricia Yl Chan, Shiwen Yuan, David J Hunter

{"title":"Osteoarthritis and cardiometabolic diseases: shared mechanisms, modifiable risk factors, and integrated management strategies.","authors":"Patricia Yl Chan, Shiwen Yuan, David J Hunter","doi":"10.1080/17512433.2026.2649611","DOIUrl":null,"url":null,"abstract":"Introduction: Osteoarthritis (OA) and cardiometabolic diseases (CMD), including metabolic syndrome, type 2 diabetes, and cardiovascular disease, are common chronic disorders sharing risk factors, mechanisms, and societal burdens. Obesity, insulin resistance, dyslipidaemia, hypertension, and inflammation link joint damage with vascular and metabolic issues. Factors such as advanced glycation end-products, adipokines, and cytokines including interleukin-6 and C-reactive protein drive systemic and local inflammation, accelerating joint deterioration and cardiovascular problems.Areas covered: We searched MEDLINE, PubMed, Embase, Cochrane, Scopus, CIAP, and Google Scholar from January 2011 to October 2025. Evidence supports a bidirectional relationship where OA worsens cardiometabolic risk via inactivity, and CMD accelerates OA through vascular and metabolic stress. Without disease-modifying drugs, lifestyle interventions like weight management and physical activity are key. Multidisciplinary care targeting shared modifiable risk factors can improve outcomes.Expert opinion: Future research should investigate shared molecular pathways using approaches like multi-omics, validate early-detection biomarkers, and assess multimodal interventions that link musculoskeletal and metabolic health. A patient-centered approach to OA and CMD offers the best chance to reduce disability and disease burden.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"341-355"},"PeriodicalIF":3.6000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2026.2649611","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Osteoarthritis (OA) and cardiometabolic diseases (CMD), including metabolic syndrome, type 2 diabetes, and cardiovascular disease, are common chronic disorders sharing risk factors, mechanisms, and societal burdens. Obesity, insulin resistance, dyslipidaemia, hypertension, and inflammation link joint damage with vascular and metabolic issues. Factors such as advanced glycation end-products, adipokines, and cytokines including interleukin-6 and C-reactive protein drive systemic and local inflammation, accelerating joint deterioration and cardiovascular problems.

Areas covered: We searched MEDLINE, PubMed, Embase, Cochrane, Scopus, CIAP, and Google Scholar from January 2011 to October 2025. Evidence supports a bidirectional relationship where OA worsens cardiometabolic risk via inactivity, and CMD accelerates OA through vascular and metabolic stress. Without disease-modifying drugs, lifestyle interventions like weight management and physical activity are key. Multidisciplinary care targeting shared modifiable risk factors can improve outcomes.

Expert opinion: Future research should investigate shared molecular pathways using approaches like multi-omics, validate early-detection biomarkers, and assess multimodal interventions that link musculoskeletal and metabolic health. A patient-centered approach to OA and CMD offers the best chance to reduce disability and disease burden.

查看原文本刊更多论文

骨关节炎和心脏代谢疾病：共同机制、可改变的危险因素和综合管理策略

骨关节炎（OA）和心血管代谢疾病（CMD），包括代谢综合征、2型糖尿病和心血管疾病，是常见的慢性疾病，具有共同的危险因素、机制和社会负担。肥胖、胰岛素抵抗、血脂异常、高血压和炎症将关节损伤与血管和代谢问题联系在一起。晚期糖基化终产物、脂肪因子和细胞因子（包括白细胞介素-6和c反应蛋白）等因素驱动全身和局部炎症，加速关节恶化和心血管问题。涵盖领域：我们检索了2011年1月至2025年10月期间的MEDLINE、PubMed、Embase、Cochrane、Scopus、CIAP和谷歌Scholar。有证据支持一种双向关系，即OA通过不活动恶化心脏代谢风险，而CMD通过血管和代谢应激加速OA。没有治疗疾病的药物，生活方式的干预，如体重管理和体育活动是关键。针对共同可改变的危险因素的多学科护理可以改善结果。专家意见：未来的研究应使用多组学等方法调查共享的分子途径，验证早期检测的生物标志物，并评估将肌肉骨骼和代谢健康联系起来的多模式干预措施。以患者为中心的OA和CMD方法提供了减少残疾和疾病负担的最佳机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.